Participated · Equity · Jun 2026

Rejuvenate Bio develops gene therapies aimed at extending healthy lifespan and treating chronic, age-associated diseases by combining advances in gene delivery, translational biology, and longevity science. The company has built a pipeline targeting clinically validated gene targets with a delivery approach designed for well-tolerated, durable expression. Rejuvenate Bio is developing therapies for companion animals with the stated goal of translating insights toward human health applications. The company was founded on research from the Wyss Institute at Harvard Medical School and is headquartered in San Diego, CA. Following the announced $6 million financing, Rejuvenate Bio has also entered a strategic R&D collaboration with Merck Animal Health to advance a targeted animal-health gene therapy program.

Participated · Series C · May 2022

TARGAN is a technology provider focused on solving pressing issues in worldwide food production. Its flagship product, WingScan, is gaining rapid traction across the United States, Europe, and South America, with new markets coming on board every month. The company states it is entering an extraordinary growth phase and intends to scale its operations significantly. Management plans to channel new capital into infrastructure development that will underpin the next wave of product launches. This strategy is aimed at accelerating market expansion and reinforcing TARGAN’s leadership in food-production technology.

Participated · Series A · Mar 2021

SomaDetect has developed an in-line sensor that emits light into milk hoses and analyzes scatter patterns to determine somatic cell counts, a direct indicator of mastitis. The device combines computer vision and deep neural networks to build algorithms that predict relevant compounds and early infections. The startup has been trialing the technology with partner Summitholm Holsteins and is planning broader beta tests at Canadian dairy farms. After beta trials the company intends to begin taking orders for the sensor; an ideal customer farm is described as around 2,000 cows. SomaDetect positions its product as a seamless, farmer-first integration into milking systems to reduce milk loss and early-detect infections that cost roughly $200 per cow per year. The company is preparing for commercialization while building customer deployments and data to refine its models. SomaDetect produces an in-line sensor that attaches to a tablet alongside the milking hose and uses light scattering, computer vision, and deep neural networks to measure somatic cell counts and other milk compounds. The sensor analyzes scatter patterns to determine cell counts, enabling twice-daily monitoring of individual cows during milking and delivering real-time alerts to farmers. SomaDetect positions this continuous monitoring as a faster, more actionable alternative to monthly lab sampling that can take a week to return results. The company is collecting data at scale and aims to transition from tens of thousands to millions of data points to improve its algorithms and product. Management sees opportunities to expand the technology into other on-farm applications such as breeding and broader milk-quality monitoring, while prioritizing earning farmers’ trust through reliable core functionality. The business faces adoption headwinds from subscription cost sensitivity among farmers but is supported by early adopters and industry partnerships. SomaDetect offers a data-driven herd-monitoring system that gives farmers actionable information to produce higher-quality milk. The company was one of two winners of Communitech’s Fierce Founders bootcamp pitch finale and received a $50,000 award. The bootcamp targets early-stage entrepreneurs at MVP or pre‑MVP stage and included 20 participating startups, nine of which pitched in the finale. As a winner, SomaDetect was invited to join the third cohort of the Fierce Founders Accelerator, a six‑month program that provides mentorship and requires entrepreneurs to match at least $30,000 in funding. The article does not disclose revenue, user metrics, prior financings, or founders beyond the award and accelerator invitation.